<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html xmlns="http://www.w3.org/1999/xhtml" lang="en" xml:lang="en"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><link rel="stylesheet" href="/css/isb.css" /><title>ProteomeXchange Dataset PXD006581</title>
</head><body bgcolor="#f4f6f8" marginwidth="0" marginheight="0">	<table width="100%" height="127" background="/images/topbackground.jpg" style="box-shadow: 0 6px 8px 0 rgba(0,0,0,0.3);">	<tr align="center"><td><a href="http://www.proteomexchange.org/" border="0"><img src="/images/proteomexchange.png"></a></td><td><a href="http://proteomecentral.proteomexchange.org/" border="0"><img src="/images/proteomecentral.png"></a></td></tr>	</table>		<!-- Main content area here --><!-- BEGIN main content -->

	 <link rel='stylesheet' id='style-css'  href='../javascript/css/patchwork.css' type='text/css' media='all' />
         <script type="text/javascript" src="/javascript/js/toggle.js"></script>
      
       <div id="main">
       <a class="linkback" href="http://proteomecentral.proteomexchange.org/cgi/GetDataset"> &lt;&lt;&lt; Full experiment listing </a>
       <div id="dataset-primary" class="site-content">
       <h1 class="dataset-title">PXD006581</h1>
    
	<div class="dataset-content">
	PXD006581 is an <b>original dataset</b> announced via ProteomeXchange.<BR><BR><div class='dataset-secthead'>Dataset Summary</div>
<table class='dataset-summary'><tr><td><b>Title</b></td><td>Repurposing tofacitinib as an anti-myeloma therapeutic to reverse growth-promoting effects of the bone marrow microenvironment</td></tr><tr><td><b>Description</b></td><td class='breakwords'>The myeloma bone marrow microenvironment drives proliferation of malignant plasma cells and promotes resistance to therapy. Interleukin-6 (IL-6) and downstream JAK/STAT signaling are thought to be central components of these microenvironment-induced phenotypes. In a prior drug repurposing screen, we identified tofacitinib, a pan-JAK inhibitor FDA-approved for rheumatoid arthritis, as an agent that may reverse the tumor-stimulating effects of bone marrow mesenchymal stromal cells.Here, we validated both in vitro, in stromal-responsive human myeloma cell lines, and in vivo, in orthotopic disseminated murine xenograft models of myeloma, that tofacitinib showed both single-agent and combination therapeutic efficacy in myeloma models.  Surprisingly, we found that ruxolitinib, an FDA-approved agent targeting JAK1 and JAK2, did not lead to the same anti-myeloma effects.  Combination with a novel irreversible JAK3-selective inhibitor also did not rescue ruxolitinib effects. RNA-seq and unbiased phosphoproteomics revealed that marrow stromal cells drive a JAK/STAT-mediated proliferative program in myeloma plasma cells, and tofacitinib reversed the large majority of these pro-growth signals. Taken together, our results suggest that tofacitinib specifically reverses the growth-promoting effects of the tumor microenvironment through blocking an IL-6-mediated signaling axis. As tofacitinib is already FDA-approved, these results can be rapidly translated into potential clinical benefits for myeloma patients.</td></tr><tr><td><b>HostingRepository</b></td><td>PRIDE</td></tr><tr><td><b>AnnounceDate</b></td><td>2018-10-24</td></tr>
                <tr><td><b>AnnouncementXML</b></td><td><a href='GetDataset?ID=PXD006581-1&outputMode=XML&test=no' target="_blank">Submission_2018-10-24_12:44:42.xml</a></td></tr>
                <tr><td><b>DigitalObjectIdentifier</b></td><td><a href="" target="_blank"></a></td></tr><tr><td><b>ReviewLevel</b></td><td>Peer-reviewed dataset</td></tr><tr><td><b>DatasetOrigin</b></td><td>Original dataset</td></tr><tr><td><b>RepositorySupport</b></td><td>Unsupported dataset by repository</td></tr><tr><td><b>PrimarySubmitter</b></td><td>Christine Lam</td></tr><tr><td><b>SpeciesList</b></td><td> scientific name: Homo sapiens (Human);  NCBI TaxID: 9606; </td></tr><tr><td><b>ModificationList</b></td><td>phosphorylated residue</td></tr><tr><td><b>Instrument</b></td><td>Q Exactive Plus</td></tr></table>
<div class='dataset-secthead'>Dataset History</div>
<table class="dataset-summary">
<tr><th>Revision</th><th>Datetime</th><th>Status</th><th>ChangeLog Entry</th></tr>
<tr><td >0</td><td >2017-05-24 05:13:20</td><td >ID requested</td><td ></td></tr>
<tr><td class="dataset-currentrev"><a href="GetDataset?ID=PXD006581-1&test=no"><span class='current'>&#9205;</span> 1</a></td><td class="dataset-currentrev">2018-10-24 12:44:43</td><td class="dataset-currentrev">announced</td><td class="dataset-currentrev"></td></tr>
</table>
<div class='dataset-secthead'>Publication List </div>
<table class='dataset-summary'>
<tr><td>Lam C, Ferguson ID, Mariano MC, Lin YT, Murnane M, Liu H, Smith GA, Wong SW, Taunton J, Liu JO, Mitsiades CS, Hann BC, Aftab BT, Wiita AP, Repurposing tofacitinib as an anti-myeloma therapeutic to reverse growth-promoting effects of the bone marrow microenvironment. Haematologica, 103(7):1218-1228(2018) [<a href="https://www.ncbi.nlm.nih.gov/pubmed?term=29622655" target="_blank">pubmed</a>]</td></tr></table>
<div class='dataset-secthead'>Keyword List </div>
<table class='dataset-summary'>
<tr><td>curator keyword: Biomedical</td></tr><tr><td>submitter keyword: human, myeloma, tofacitinib, bone marrow microenvironment,  LC-MSMS, LFQ</td></tr></table>
<div class='dataset-secthead'>Contact List </div>
<table class='dataset-summary'>
<tr><th colspan='2'>Arun Paul Wiita</th></tr>
<tr><td>contact affiliation</td><td>Department of Laboratory Medicine, Wiita Lab, University of California San Francisco</td></tr><tr><td>contact email</td><td>Arun.Wiita@ucsf.edu</td></tr><tr><td>lab head</td><td></td></tr><tr><th colspan='2'>Christine Lam</th></tr>
<tr><td>contact affiliation</td><td>UCSF</td></tr><tr><td>contact email</td><td>christine.yt.lam@ucsf.edu</td></tr><tr><td>dataset submitter</td><td></td></tr></table>
<div class='dataset-secthead'>Full Dataset Link List </div>
<table class='dataset-summary'>
<tr><td><a href=ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2018/10/PXD006581 target="_blank">Dataset FTP location</a></td></tr><tr><td><a href=http://www.ebi.ac.uk/pride/archive/projects/PXD006581 target="_blank">PRIDE project URI</a></td></tr></table>

		 <div class='dataset-secthead'>Repository Record List </div>
                 <div id="less" onclick='toggle("less","more","repositoryRecordList")' title='Expand Record List'>[ + ]</div>
		 <div id="more" onclick='toggle("more","less","repositoryRecordList")' title='Hide Record List' style='display: none'>[ - ]</div>
		 <ul id="repositoryRecordList" style='display: none'>
        <li>PRIDE<ol><li><a href="http://www.ebi.ac.uk/pride/archive/projects/PXD006581" target="_blank">PXD006581</a><ol><li>Label: PRIDE project</li><li>Name: Repurposing tofacitinib as an anti-myeloma therapeutic to reverse growth-promoting effects of the bone marrow microenvironment</li></ol></li></li></ul>

      
	 </div><!-- #content -->
	 </div><!-- #primary .site-content -->
	 </div><!-- #main -->
      <!-- END main content -->	<!-- Begin Footer -->	<br clear="all">	<div class="footer">	<table width="100%"><tr>	<td style="vertical-align:top; text-align:left; padding: 10px;">If you have a question or comment about ProteomeXchange, please <a href="http://www.proteomexchange.org/contact">contact us</a>!<BR>	<a href="http://www.proteomexchange.org/subscribe/index.html"><img width="70" height="20" src="/images/subscribe_button-small.jpg"><font size="+1" color="#aa0000"> to receive all new ProteomeXchange dataset release announcements!</font></a>	</td>	<td style="text-align:right; padding: 10px;">	<a class="logolink" target="_blank" href="http://www.ebi.ac.uk/"><img src="/images/ebi_footer_logo.png"></a>&nbsp;&nbsp;&nbsp;&nbsp;	<a class="logolink" target="_blank" href="http://www.isbscience.org/"><img src="/images/isb.jpg"></a>&nbsp;&nbsp;&nbsp;&nbsp;	<a class="logolink" target="_blank" href="http://ec.europa.eu/research/fp7/index_en.cfm"><img src="/images/capacities.png"></a>	</td></tr></table>	</div>				</body></html>